PMID- 36248412
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221019
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - KRT17 Accelerates Cell Proliferative and Invasive Potential of Laryngeal Squamous 
      Cell Carcinoma (LSCC) through Regulating AKT/mTOR and Wnt/beta-Catenin Pathways.
PG  - 6176043
LID - 10.1155/2022/6176043 [doi]
LID - 6176043
AB  - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is a prevalent malignant 
      tumor of the head and neck with a dismal prognosis. Keratin17 (KRT17) has been 
      proven to serve as an oncogene in various cancers, but it has never been explored 
      in LSCC. We proposed to assess the impact and possible mechanisms of KRT17 in the 
      development of LSCC. METHODS: Quantitative reverse transcription-PCR (qRT-PCR) 
      was utilized to examine the mRNA levels. The Kaplan-Meier method was used to 
      calculate the relationship between KRT17 expression and survival curves in LSCC 
      patients. Cell counting kit-8 (CCK-8), colony formation, and flow cytometry 
      assays were utilized to estimate LSCC cell proliferation. The migration and 
      invasion abilities of LSCC cells were ascertained by wound-healing and transwell 
      assays. Immunohistochemical and western blot assays were utilized to appraise 
      protein levels. The xenograft tumor model was used to determine the effect of 
      KRT17 on tumor growth. RESULTS: In the present study, KRT17 was extremely high in 
      LSCC tissues and cells and correlated with a poor prognosis. Inhibition of KRT17 
      weakens cell proliferative, migratory, and invasive abilities in LSCC and 
      contributes to cell cycle arrest. Besides, we approved that knockdown of KRT17 
      extraordinarily restrained the xenograft tumor growth in vivo. We preliminarily 
      investigated the role of KRT17 on the AKT/mTOR and Wnt/beta-catenin signaling axes 
      and found that these signaling pathways were largely blocked by KRT17 deletion. 
      CONCLUSION: Collectively, we uncovered that exhaustion of KRT17 suppresses LSCC 
      progression through coordinating AKT/mTOR and Wnt/beta-catenin signaling axes, 
      illustrating KRT17 as a promising biomarker for making strides in LSCC treatment.
CI  - Copyright (c) 2022 JianQiu Wang et al.
FAU - Wang, JianQiu
AU  - Wang J
AUID- ORCID: 0000-0003-0501-7410
AD  - Department of Otolaryngology, The First Affiliated Hospital, Huzhou University, 
      The First People's Hospital of Huzhou, Huzhou 313000, Zhejiang, China.
FAU - Lan, Longjiang
AU  - Lan L
AUID- ORCID: 0000-0002-0426-0294
AD  - Department of Otolaryngology, The First Affiliated Hospital, Huzhou University, 
      The First People's Hospital of Huzhou, Huzhou 313000, Zhejiang, China.
FAU - Ma, Bingliang
AU  - Ma B
AUID- ORCID: 0000-0002-3735-5142
AD  - Department of Otolaryngology, The First Affiliated Hospital, Huzhou University, 
      The First People's Hospital of Huzhou, Huzhou 313000, Zhejiang, China.
FAU - Ren, Gang
AU  - Ren G
AUID- ORCID: 0000-0002-0107-0524
AD  - Department of Otolaryngology, The First Affiliated Hospital, Huzhou University, 
      The First People's Hospital of Huzhou, Huzhou 313000, Zhejiang, China.
FAU - Yin, ChengYi
AU  - Yin C
AUID- ORCID: 0000-0002-1461-4244
AD  - Department of Otolaryngology, The First Affiliated Hospital, Huzhou University, 
      The First People's Hospital of Huzhou, Huzhou 313000, Zhejiang, China.
LA  - eng
PT  - Journal Article
DEP - 20221005
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC9556256
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2022/10/18 06:00
MHDA- 2022/10/18 06:01
PMCR- 2022/10/05
CRDT- 2022/10/17 05:06
PHST- 2022/06/20 00:00 [received]
PHST- 2022/08/11 00:00 [revised]
PHST- 2022/08/24 00:00 [accepted]
PHST- 2022/10/17 05:06 [entrez]
PHST- 2022/10/18 06:00 [pubmed]
PHST- 2022/10/18 06:01 [medline]
PHST- 2022/10/05 00:00 [pmc-release]
AID - 10.1155/2022/6176043 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Oct 5;2022:6176043. doi: 
      10.1155/2022/6176043. eCollection 2022.